Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-targeted vaccines.

T Keler1, L He, V Ramakrishna

  • 1Celldex Therapeutics Inc, Phillipsburg, NJ 08865, USA. tkeler@celldextherapeutics.com

Oncogene
|May 29, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Constraints on Cosmic Strings Using Data from the Third Advanced LIGO-Virgo Observing Run.

Physical review letters·2021
Same author

New insights into Brunner syndrome and potential for targeted therapy.

Clinical genetics·2015
Same author

The Arabo-Islamic migrations in Madagascar: first genetic study of the GM system in three Malagasy populations.

International journal of immunogenetics·2011
Same author

Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2010
Same author

Loop-mediated isothermal amplification (LAMP) assay for detection of Theileria sergenti infection targeting the p33 gene.

Veterinary parasitology·2010
Same author

Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease.

The Journal of international medical research·2010
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
Same journal

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
Same journal

Correction: Liver-specific SIRT1 knockout-induced hyperglycemia promotes spontaneous lung adenocarcinomas through HSF1-MDM2.

Oncogene·2026
Same journal

Correction: 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.

Oncogene·2026
See all related articles

Antibody-targeted vaccines (ATV) deliver antigens to antigen-presenting cells (APCs) to stimulate adaptive immunity against cancer or infections. ATVs are also being explored for treating autoimmune diseases and preventing transplant rejection.

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Antibodies' specific binding properties are ideal for targeted payload delivery.
  • Antibody-drug conjugates are established cancer therapies.
  • Antibody-targeted vaccines (ATVs) leverage antibody specificity to target antigens to antigen-presenting cells (APCs).

Purpose of the Study:

  • To explore the potential of antibody-targeted vaccines (ATVs) in cancer therapy and immune modulation.
  • To review the development and clinical application of ATVs.
  • To discuss strategies for optimizing ATV efficacy.

Main Methods:

  • Review of existing literature on ATVs and their applications.
  • Analysis of studies investigating ATV-induced immune responses (humoral and cellular).

Related Experiment Videos

  • Evaluation of strategies to enhance ATV efficacy, including adjuvants and co-stimulatory agents.

    • Main Results:

    • ATVs can induce humoral immunity without adjuvants.
    • Targeting C-type lectin receptors with ATVs elicits potent T-cell responses.
    • ATVs can induce antigen-specific tolerance, offering potential for autoimmune disease treatment and transplant tolerance.

    Conclusions:

    • ATVs represent a promising class of antibody-based therapeutics.
    • Optimizing ATV efficacy requires careful selection of adjuvants and immunostimulatory agents.
    • ATVs have broad therapeutic potential beyond cancer, including autoimmune diseases and transplantation.